Immunologic Deficiency Syndromes
18
2
2
12
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
11.1%
2 terminated out of 18 trials
85.7%
-0.8% vs benchmark
22%
4 trials in Phase 3/4
42%
5 of 12 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 12 completed trials
Clinical Trials (18)
Sequential Transplantation of UCBSCs and Islet Cells in Children and Adolescents With Monogenic Immunodeficiency T1DM
Strimvelis Registry Study to Follow-up Patients With Adenosine Deaminase Severe Combined Immunodeficiency (ADA-SCID)
ADA Gene Transfer Into Hematopoietic Stem/Progenitor Cells for the Treatment of ADA-SCID
Genetic Study of Immunodeficiency: Search for New Genetic Causes for Primary Immunodeficiencies
Novel Mechanisms and Approaches to Treat Neonatal Sepsis
Study of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency
Efficacy and Tolerability of ABBC1 in Volunteers Receiving the Influenza or Covid-19 Vaccine
Retrospective Non-interventional Analysis of Opportunistic Infections in Immunocompromised and Frail Patients
Stem Cell Transplant for Immunologic or Histiocytic Disorders
Efficacy, Safety and Kinetics Study of Octagam 10% in Primary Immunodeficiency Diseases
Feasibility of Measuring Immune Resp, Activation in Foreskin/Mucosa in HIV-, Uncircumcised High-HIV-risk MSM, Lima Peru
A Clinical Study of Intravenous Immunoglobulin
Effects of Orally Administered Beta-glucan on Leukocyte Function in Humans
Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies
Studies of the Immune Response in Normal Subjects and Patients With Disorders of the Immune System
A Pilot Study of the Combination of Retinoic Acid and Interferon-Alpha2a for the Treatment of Lymphoproliferative Disorders in Children With Immunodeficiency Syndromes
Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis
Randomized Study of Two Doses of Oral Valacyclovir in Immunocompromised Patients With Uncomplicated Herpes Zoster